Skip to
  1. Homepage
  2. Rare diseases
  3. Search
Simple search

Simple search

*
(*) mandatory field





 

Other search option(s)

Gray platelet syndrome

ORPHA721
Synonym(s) Alpha storage pool deficiency
GPS
Platelet alpha-granule deficiency
Prevalence <1 / 1 000 000
Inheritance Autosomal dominant
or Autosomal recessive
Age of onset Childhood
ICD-10
  • D69.1
OMIM
UMLS
  • C0272302
MeSH
  • D055652
MedDRA -

Summary

Disease definition

Gray platelet syndrome (GPS) is a rare inherited bleeding disorder characterized by macrothrombocytopenia, myelofibrosis, splenomegaly and typical gray appearance of platelets on Wright stained peripheral blood smear.

Epidemiology

Exact prevalence of the disorder is not known. About 60 cases from various populations around the world have been described in the literature to date. It affects males and females equally.

Clinical description

Onset of clinical symptoms is generally in the neonatal period or in early childhood while age of diagnosis is variable. Presenting features include low platelet counts, easy bruising (petechiae), prolonged bleeding and epistaxis. Patients often have myelofibrosis and splenomegaly. Bleeding tendency is usually mild to moderate in GPS patients with mild thrombocytopenia. However, thrombocytopenia and myelofibrosis in GPS are progressive in nature; GPS may result in fatal hemorrhage especially in adulthood when platelet counts are further decreased. Female patients may develop menorrhagia.

Etiology

GPS is caused by mutations in the NBEAL2 gene. Absence or marked reduction of alpha-granules in platelets underlie the disorder. Alpha-granules are the most abundant vesicles in platelets and store proteins that promote platelet adhesiveness and wound healing when secreted during platelet activation.

Diagnostic methods

Diagnosis is based on clinical findings and requires demonstration of absence or marked reduction of alpha-granules by electron microscopy (EM). Absence of alpha-granules is an isolated finding in GPS; dense bodies and other platelet organelles and polymorphonuclear leukocytes are normal on EM. Peripheral smears show typical large, pale gray platelets. Most patients also have high serum vitamin B12 levels. Bone marrow sampling is not required for diagnosis of GPS, but might be needed to evaluate myelofibrosis occurring in GPS and to exclude other disorders.

Differential diagnosis

Differential diagnosis includes other platelet disorders such as macrothrombocytopenias (Bernard-Soulier syndrome, MYH9-related thrombocytopenia, macrothrombocytopenia with mitral valve insufficiency, Mediterranean macrothrombocytopenia), idiopathic thrombocytopenic purpura (ITP) (see these terms), as well as other disorders with hypogranular or gray platelets such as myelodysplastic syndrome (MDS, see this term), myocardial infarction, other causes of hypersplenism, and congenital conditions such as alpha-delta granule deficiency, white platelet syndrome and Quebec platelet disorder (see these terms). Electron microscopy of platelets differentiates GPS from the autosomal dominant variant and from the X-linked variant described as X-linked thrombocytopenia with thalassemia, caused by mutations in GATA1 gene (see this term). These variants display abnormalities not limited to alpha-granules.

Antenatal diagnosis

Prenatal diagnosis is possible if the NBEAL2 mutation has been identified in the family.

Genetic counseling

GPS is inherited in an autosomal recessive manner (autosomal dominant inheritance has been reported in only 1 family). Siblings of an affected patient are at 25 % risk for GPS, while the risk for offspring of a GPS patient is not significantly higher than for the general population.

Management and treatment

There is no specific treatment but management involves anticipating and preventing risks of bleeding (e.g. possible platelet transfusions before surgery). Treatment may include administration of desmopressin. Splenectomy should be considered to increase the platelet counts in patients whose platelet counts decrease to approximately 30,000/microliter.

Prognosis

Prognosis is generally good early in life when thrombocytopenia is mild. GPS patients with platelet counts less than 30,000/microliter are at risk for life-threatening bleeding.

Expert reviewer(s)

  • Dr William GAHL
  • Dr Meral GUNAY-AYGUN

(*) Required fields.

Attention: Only comments seeking to improve the quality and accuracy of information on the Orphanet website are accepted. For all other comments, please send your remarks via contact us. Only comments written in English can be processed.


Captcha image

Detailed information

Summary information
Get Acrobat Reader
The documents contained in this web site are presented for information purposes only. The material is in no way intended to replace professional medical care by a qualified specialist and should not be used as a basis for diagnosis or treatment.